Current status of pharmacological treatment of colorectal cancer

• Published in: World journal of gastrointestinal oncology 2014-06, Vol.6 (6), p.177-183
• Main Authors: Akhtar, Reyhan, Chandel, Shammy, Sarotra, Pooja, Medhi, Bikash
• Format: Article
• Language: English
• Subjects: Systematic Review
• ISSN: 1948-5204; 1948-5204
• DOI: 10.4251/wjgo.v6.i6.177

To review the clinical trials for the development in drugs for chemotherapeutic treatment of colorectal cancer (CRC). A systematic review identified randomized controlled trials (RCTs) assessing drugs for the treatment of CRC or adenomatous polyps from www.clinicaltrials.gov. Various online medical databases were searched for relevant publications. Combination treatment regimens of standard drugs with newer agents have been shown to improve overall survival, disease-free survival, time to progression and quality of life compared to that with standard drugs alone in patients with advanced colorectal cancer. The FOLFOXIRI regimen has been associated with a significantly higher response rate, progression-free survival and overall survival compared to the FOLFIRI regimen. Oxaliplatin plus intravenous bolus fluorouracil and leucovorin has been shown to be superior for disease-free survival when compared to intravenous bolus fluorouracil and leucovorin. In addition, oxaliplatin regimens were more likely to result in successful surgical resections. First line treatment with cetuximab plus fluorouracil, leucovorin and irinotecan has been found to reduce the risk of metastatic progression in patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases. The addition of bevacizumab has been shown to significantly increase overall and progression-free survival when given in combination with standard therapy.